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O-GlcNAcylation is the reversible addition of single O-linked β-D-N-acetylglucosamine (O-GlcNAc)
moieties to serine or threonine residues of proteins. This post-translational modification has been
shown to occur in many nuclear and cytosolic proteins [1]. An extensive crosstalk between O-
GlcNAcylation and phosphorylation has been described [2]. There are two enzymes implicated in
this process: β-N-acetyl-glucosaminyl transferase (OGT) adding GlcNAc moieties, and β-N-
acetylglucosaminidase (OGA) removing these moieties [3, 4]. It has been demonstrated using high
throughput proteomic analysis that the epidermal growth factor receptor (EGFR) type III of
Drosophila melanogaster undergoes O-GlcNAcylation [5]. We present experimental evidences
suggesting that the EGFR from human carcinoma epidermoid A431 cells is subjected to O-
GlcNAcylation. We detected a positive O-GlcNAcylation signal in immunoprecipitated EGFR using
immunoblot and two distinct specific anti-O-GlcNAc antibodies. Conversely, the presence of EGFR
was detected by immunoblot among the O-GlcNAcylated proteins immunoprecipitated with an anti-
O-GlcNAc antibody. These signals were enhanced when Thiamet G, a highly specific OGA
inhibitor, was present. Most significantly, we detected a positive O-GlcNAcylation signal in
immunoprecipitated and N-deglycosylated EGFR using peptide-N-glycosidase F (PNGase F), and
from tunicamycin-treated cells when were metabolically labeled with azido-GlcNAc, biotinylated
and probed with streptavidin-labeled peroxidase. Finally, we performed O-GlcNAcylation assay in
vitro using immunoprecipitated EGFR and OGT in the presence of the substrate UDP-GlcNAc,
which resulted in the enhancement of the EGFR O-GlcNAcylation signal as detected by
immunoblot. We conclude that the EGFR from A431 tumor cells is subjected to O-GlcNAcylation
and this may regulate the functionality of the receptor.
ABSTRACT
INTRODUCTION
The occurrence of O-GlcNAc at Ser and Thr
residues has been recognized as an abundant
posttranslational modification of a myriad of
cellular proteins, playing important regulatory
roles and controlling critical cellular functions
(Figure 2). Alterations in the systems involved in
protein O-GlcNAcylation have been implicated
in the development of some neurodegenerative
ailments such as Alzheimer’s disease, cancer,
as well type 2 diabetes mellitus [1].
In silico analysis suggests that Thr654 and
Ser1046/1047 of the human EGFR could be
targeted by O-GlcNAcylation, although no
experimental evidence has been provided so far
to demonstrate this assertion [6]. In this report
we shall provide proof that indeed the human
EGFR could be subjected to O-GlcNAcylation in
a tumor cell line.
The EGFR is a transmembrane glycoprotein that
belongs to the ErbB receptor tyrosine kinase family.
Its structure consists of an extracellular region which
is responsible for ligand binding, a single
transmembrane segment and a cytosolic region that
contains a juxtamembrane domain, a tyrosine
kinase domain and a C-terminal tail (Figure 1).
Binding of a variety of ligands, including EGF, TGF-
a, and HB-EGF among others, to the EGFR leads to
the homo-dimerization of the receptor or hetero-
dimerization with other ErbB family members and
activation of its intrinsic tyrosine kinase followed by
autо(trans)-phosphorylation at multiple tyrosine
residues located in the C-terminal tail. These sites
are docking places for different cytosolic proteins
containing SH2 and PTB adaptor proteins and
transduction complexes to activate signaling routes
such as the MAPK, PI3K/AKT, PLCg/PKC, and the
STAT pathways (Figure 1). The activation of these
signaling pathways results in cell cycle
progression/proliferation, cell migration, cell survival
and differentiation. EGFR is frequently
overexpressed and/or mutated in many solid tumors
thus contributing to cancerogenesis [7].
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RESULTS
Figure 3. Detection of O-GlcNAcylation signal in immunoprecipitated EGFR by Western blot.
(A, B) The EGFR was immunoprecipitated (IP) from an A431 cell extract using an anti-EGFR
antibody and the immunocomplex was incubated in the absence (-) and presence (+) of PNGase F
to remove N-glycans. The samples were immunoblotted (WB) with the anti-O-GlcNAc antibodies
CTD110.6 (A) and RL2 (B) as indicated. The PVDF membranes were stripped and probed with an
anti-EGFR antibody as loading control. Mock IP was performed using a non-relevant IgG as
negative control. Upper and lower arrowheads point the native and N-deglycosylated EGFR,
respectively.
Figure 4. Effects of OGT and OGA inhibitors on the EGFR O-GlcNAcylation signal. (A) A431
cells were incubated overnight in the absence (None) and presence of 20 µM Thiamet G or 2 mM
BADGP as indicated. The samples were immunoprecipitated (IP) using an anti-EGFR antibody and
the immunocomplex was incubated in the absence (-) and presence (+) of PNGase F to remove N-
glycans, processed by SDS-PAGE and Western blots (WB) and probed with an anti-O-GlcNAc
antibody (RL2). The PVDF membrane was stripped and probed with an anti-EGFR antibody as
loading control. (B) The plot presents the mean ± SEM (n = 3) EGFR O-GlcNAcylation from a set of
experiments similar to the one shown in A measuring the densitometry of the O-GlcNAcylated band
corrected by loading as determined by the total EGFR signal. (*) p < 0.05 as determined by the
Student’s t test. Upper and lower arrowheads point the native and N-deglycosylated EGFR,
respectively. (C) A431 cells were incubated overnight in the absence (None) and presence of 20
µM Thiamet G or 2 mM BADGP as indicated. The proteins were immunoprecipitated (IP) using an
anti-O-GlcNAc antibody (RL2) and the immunocomplex processed by SDS-PAGE and Western
blots (WB) using an anti-EGFR antibody. A mock IP was performed using a non-relevant IgG as
negative control. The heavy chain IgG band stained with Fast Green is shown.
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Figure 6. Detection of O-GlcNAcylation signal in immunoprecipitated EGFR from azido-
GlcNAc-treated cells. (A) Serum-starved A431 cells were treated overnight with 40 µM azido-
GlcNAc (GlcNAz) and incubated as indicated in the absence (-) and presence (+) of 10 nM EGF
during 30 min. Thereafter, the EGFR was immunoprecipitated (IP) and where indicated treated
with PNGase F to remove N-glycans. The samples were subjected to biotinylation and overlaid
with streptavidin-HRP to detect GlcNAz-labeled proteins. Immunoprecipitated EGFR from cells
non-treated with GlcNAz (No GlcNAz) and a mock IP are shown as negative controls. Protein
staining of the immunoprecipitated EGFR band with Fast Green is shown as loading control. (B)
A431 cells were treated overnight with 1 µg/ml tunicamycin, the EGFR was immunoprecipitated
(IP) and where indicated treated with PNGase F to remove potential residual N-glycans. The
samples were subjected to biotinylation and overlaid with streptavidin-HRP to detect GlcNAz-
labeled proteins. Duplicate samples were probed with an anti-EGFR antibody. Immunoprecipitated
EGFR from cells non-treated with GlcNAz (No GlcNAz) and a mock IP are shown as negative
controls. Upper and lower black arrowheads (A, B) point the native and N-deglycosylated EGFR,
respectively, and the gray arrowhead (A) points to a partially degraded N-deglycosylated EGFR.
Figure 7. Enhanced O-GlcNAcylation of EGFR upon in vitro reaction catalyzed by
immunoprecipitated OGT. (A) OGT and EGFR were independently immunoprecipitated from
A431 cells. Thereafter, the immunoprecipitated EGFR was incubated in the absence (-) and
presence (+) of immunoprecipitated OGT and the O-GlcNAcylation reaction was performed upon
addition of UDP-GlcNAc. The samples were immunoblotted (WB) with an anti-O-GlcNAc antibody
(CTD110.6) as indicated. The EGFR as detected with an anti-EGFR antibody and the heavy chain
of IgG stained with Fast Green are shown as loading controls. (B) The plot presents the mean ±
range EGFR O-GlcNAcylation in the absence (None) and presence of OGT from two independent
experiments similar to the one shown in A measuring the densitometry of the O-GlcNAcylated
EGFR band corrected by loading as determined by protein staining with Fast Green.
MAJOR FINDINGS & CONCLUSION
1. Removal of N-glycans in the EGFR enhances the reactivity of the anti-O-GlcNAc antibodies.
2. Inhibition of OGA leads to a significant increase in the EGFR O-GlcNAcylation signal.
3. N-deglycosylation did not diminish the azido-GlcNAc signal of the EGFR.
4. OGT O-GlcNAcylates the EGFR in an in vitro assay system.
5. We conclude that the human EGFR in A431 tumor cells is subjected to O-GlcNAcylation.
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Figure 1. The EGFR signaling pathway
Figure 2. Reversible O-GlcNAcylation of 
Ser/Thr in a target protein.
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Figure 5. Effects of OGT and OGA inhibitors on cell migration. Artificial wounds were performed in
confluent monolayers of A431 cells in the absence (None) or in the presence of the OGT inhibitor
BADGP (1 mM) and the OGA inhibitor Thiamet G (100 μM). Photographs were taken at different times
in order to follow the closure of the wounds using a Zeiss Cell Observer system. (A) A typical set of
photographs taken at different times are shown. (B) The plot represents the mean ± SEM (n = 4) of the
closing of the wound in the different conditions. Significant differences when comparing the curves
using the two-way ANOVA test are shown (*** p < 0.0001).
